PDCI Market Access Inc. (PDCI), in collaboration with Connex Health Consulting, is excited to announce the launch of its 2020 Private Payer Product Listing Agreement (PLA) study!

The objective of this research is to share insights about the private payer PLA landscape among pharmaceutical stakeholders in Canada. Today, in the study’s first phase, PDCI is requesting pharmaceutical manufacturers and private payers participate in a 20-minute survey about their company’s private payer PLA experiences.

Data collected from this survey will remain confidential and participants will remain anonymous.

Participants will receive early access to the anonymized survey results.

In the second phase of this study, PDCI will invite interested stakeholders (including but not limited to manufacturers, payers, associations, patient representatives, etc.) to participate in qualitative telephone interviews to share additional insights about the Private Payer PLAs landscape in Canada today and their expectations for PLAs in the years to come. Please stay tuned for more information as the study proceeds.

This study will update the Private Payer PLA study conducted by PDCI and H3 Consulting in 2015 (results available here).

If you are a manufacturer or private payer representative interested in or responsible for private payer PLAs, please contact julia.shen@pdci.ca for more information.